Timing of Shingles Vaccination After a Shingles Outbreak

Rationale for the 2-Month Waiting Period

• The 2-month interval recommendation is based on documented evidence showing this is the minimum interval between an episode of herpes zoster and potential recurrence 1, 2
• The waiting period allows for complete resolution of the acute phase of herpes zoster, abatement of symptoms, and recovery of the immune system to optimize vaccine response 2, 3

Country-Specific Recommendations

• Different countries have varying recommendations for the time frame between a shingles episode and vaccination: USA and Germany recommend waiting until the acute stage has resolved and symptoms have abated, while Austria recommends waiting at least 2 months, and Canada, Ireland, and Australia recommend waiting at least 1 year 1, 2

Risk of Recurrence Without Vaccination

• A recent US study with 5.6 years of follow-up showed a cumulative incidence of shingles recurrence of 2.5% at 2 years, 4.8% at 4 years, 6.6% at 6 years, 8.0% at 8 years, and 10.3% at 10 years 1, 2, 3

Vaccine Options After Shingles

• Both available vaccines, Recombinant zoster vaccine (RZV, Shingrix) and Live zoster vaccine (ZVL, Zostavax), can be administered after a shingles episode, with RZV being the preferred option due to higher efficacy and stronger immune response 1, 2, 3
• Complete vaccination with 2 doses of RZV is strongly recommended for optimal protection 1

Clinical Pitfalls to Avoid

• Waiting too long after the 2-month minimum period can increase the risk of recurrence, and confusing the waiting period after shingles with the interval between vaccine doses should be avoided 1, 2
• Live zoster vaccine (ZVL) should not be administered to immunocompromised patients 4
• Older adults who have had shingles should not be missed as an opportunity for vaccination, as they remain at risk for recurrence 1, 2

Shingles Vaccination Guidelines

Vaccine Administration

• The National Comprehensive Cancer Network recommends administering the recombinant zoster vaccine (RZV, Shingrix) as a 2-dose series, with doses given 2-6 months apart, for adults aged ≥50 years and immunocompromised adults aged ≥18 years 5
• For immunocompromised adults aged ≥18 years, the second dose of RZV can be given 1-2 months after the first dose if they would benefit from a shorter vaccination schedule, as recommended by the National Comprehensive Cancer Network 5

Contraindications and Precautions

• The use of live zoster vaccine (Zostavax) is contraindicated in immunocompromised patients, as stated by Autoimmunity Reviews and Gut 6, 7

Timing of Shingles Vaccine After Acute Shingles Episode

Special Considerations for Immunocompromised Patients

• For patients on immunosuppressive therapy, consider deferring vaccination until after holding immunosuppressive medication for an appropriate period before and 4 weeks after vaccination to ensure robust immune response, as recommended by the Journal of Microbiology, Immunology and Infection 8

Timing of Shingles Vaccine After Acute Infection

Special Population Considerations

• For allogeneic hematopoietic stem cell transplant recipients, the US CDC recommends administering the Shingrix vaccine at least 6-12 months post-transplantation, with some guidelines suggesting at least 9 months, to ensure a robust immune response 9
• For autologous HSCT recipients, vaccination with Shingrix can begin 50-70 days post-transplantation, as recommended by the Journal of Microbiology, Immunology and Infection 9

Timing of Zoster Vaccination After a Herpes Zoster Outbreak

Special Considerations for Immunocompromised Patients

• For patients on immunosuppressive therapy, the Centers for Disease Control and Prevention recommends completing the vaccination series before initiating highly immunosuppressive therapy, or deferring vaccination until after holding immunosuppressive medication for an appropriate period, to ensure a robust immune response 10
• The Clinical Infectious Diseases guideline suggests that only the recombinant zoster vaccine (Shingrix) is appropriate for immunocompromised patients, as the live-attenuated zoster vaccine (Zostavax) is contraindicated due to the risk of disseminated VZV infection 10

Vaccination Recommendations After Disseminated Herpes Zoster

Contraindications During Active Disease

• Active disseminated herpes zoster reflects marked immune dysfunction, making any vaccination during the acute phase unsafe and potentially harmful. [Clinical Infectious Diseases] 11

• Live‑attenuated zoster vaccine (Zostavax) is absolutely contraindicated in patients who have experienced disseminated zoster because they are, by definition, immunocompromised and at risk for uncontrolled vaccine‑strain viral replication. [Clinical Infectious Diseases] 11

Preferred Vaccine Choice

• The recombinant zoster vaccine (Shingrix) is the only appropriate vaccine for patients after disseminated zoster; it is non‑live and therefore safe for immunocompromised individuals. [Clinical Infectious Diseases] 11

• Shingrix is a non‑live, recombinant subunit vaccine that contains only a VZV glycoprotein E antigen, providing a safe immunogenic platform for patients with compromised immunity. [Annals of the Rheumatic Diseases] 12

Timing of Vaccination After Recovery

• Shingrix should be administered no earlier than 2 months after complete clinical resolution of the acute disseminated episode, allowing lesion healing and immune recovery to optimize vaccine response. [Clinical Infectious Diseases] 11

Coordination With Immunosuppressive Therapy

• The 2‑dose Shingrix series should ideally be finished before initiating or resuming highly immunosuppressive therapy to ensure maximal protective immunity. [Clinical Infectious Diseases] 11

• In highly immunocompromised patients, live‑attenuated vaccines (including Zostavax) should be avoided altogether, reinforcing the exclusive use of the recombinant formulation. [Clinical Infectious Diseases] 11 [additional citation @23@]